Curis, Inc. (CRIS) Plunges as Death Forces FDA to Slap Partial Hold on Experimental Cancer Drug; Stock Falls -26.48% at Market Close (November 6, 2013)
11/6/2013 7:25:33 AM
Curis Inc said it had been stopped from enrolling any new patients in an early stage trial of its experimental cancer drug following the death of a patient who had liver failure. Curis's shares fell 10 percent in premarket trading after the U.S. Food and Drug Administration placed a partial hold on the trial. The company said the FDA was seeking additional data on patients treated with the drug, CUDC-427.
Help employers find you! Check out all the jobs and post your resume.
comments powered by